🚀 VC round data is live in beta, check it out!
PolyPeptide Valuation Multiples
Discover revenue and EBITDA valuation multiples for PolyPeptide and similar public comparables like R&G PharmaStudies, Oxford BioMedica, Fortrea, AbCellera and more.
PolyPeptide Overview
About PolyPeptide
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
Founded
1952
HQ
Employees
1.3K
Website
Financials (LTM)
EV
$1B
PolyPeptide Financials
PolyPeptide reported last 12-month revenue of $470M and EBITDA of $55M.
In the same LTM period, PolyPeptide generated $79M in gross profit, $55M in EBITDA, and had net loss of ($27M).
Revenue (LTM)
PolyPeptide P&L
In the most recent fiscal year, PolyPeptide reported revenue of $449M and EBITDA of $47M.
PolyPeptide expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $470M | XXX | $449M | XXX | XXX | XXX |
| Gross Profit | $79M | XXX | $76M | XXX | XXX | XXX |
| Gross Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA | $55M | XXX | $47M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 10% | XXX | XXX | XXX |
| EBIT Margin | 1% | XXX | 2% | XXX | XXX | XXX |
| Net Profit | ($27M) | XXX | ($24M) | XXX | XXX | XXX |
| Net Margin | (6%) | XXX | (5%) | XXX | XXX | XXX |
| Net Debt | — | — | $40M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
PolyPeptide Stock Performance
PolyPeptide has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
PolyPeptide's stock price is $32.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -1.0% | XXX | XXX | XXX | $-0.74 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPolyPeptide Valuation Multiples
PolyPeptide trades at 2.3x EV/Revenue multiple, and 19.8x EV/EBITDA.
EV / Revenue (LTM)
PolyPeptide Financial Valuation Multiples
As of March 21, 2026, PolyPeptide has market cap of $1B and EV of $1B.
Equity research analysts estimate PolyPeptide's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PolyPeptide has a P/E ratio of (38.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 19.8x | XXX | 23.2x | XXX | XXX | XXX |
| EV/EBIT | 306.9x | XXX | 109.0x | XXX | XXX | XXX |
| EV/Gross Profit | 13.8x | XXX | 14.2x | XXX | XXX | XXX |
| P/E | (38.6x) | XXX | (43.6x) | XXX | XXX | XXX |
| EV/FCF | (23.7x) | XXX | (30.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PolyPeptide Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
PolyPeptide Margins & Growth Rates
PolyPeptide's revenue in the last 12 month grew by 20%.
PolyPeptide's revenue per employee in the last FY averaged $0.4M.
PolyPeptide's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PolyPeptide's rule of X is 62% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
PolyPeptide Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | 68% | XXX | 81% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 62% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 15% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
PolyPeptide Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| R&G PharmaStudies | XXX | XXX | XXX | XXX | XXX | XXX |
| Oxford BioMedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Fortrea | XXX | XXX | XXX | XXX | XXX | XXX |
| AbCellera | XXX | XXX | XXX | XXX | XXX | XXX |
| Evotec | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PolyPeptide M&A Activity
PolyPeptide acquired XXX companies to date.
Last acquisition by PolyPeptide was on XXXXXXXX, XXXXX. PolyPeptide acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by PolyPeptide
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPolyPeptide Investment Activity
PolyPeptide invested in XXX companies to date.
PolyPeptide made its latest investment on XXXXXXXX, XXXXX. PolyPeptide invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by PolyPeptide
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PolyPeptide
| When was PolyPeptide founded? | PolyPeptide was founded in 1952. |
| Where is PolyPeptide headquartered? | PolyPeptide is headquartered in Switzerland. |
| How many employees does PolyPeptide have? | As of today, PolyPeptide has over 1K employees. |
| Is PolyPeptide publicly listed? | Yes, PolyPeptide is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of PolyPeptide? | PolyPeptide trades under PPGN ticker. |
| When did PolyPeptide go public? | PolyPeptide went public in 2021. |
| Who are competitors of PolyPeptide? | PolyPeptide main competitors are R&G PharmaStudies, Oxford BioMedica, Fortrea, AbCellera. |
| What is the current market cap of PolyPeptide? | PolyPeptide's current market cap is $1B. |
| What is the current revenue of PolyPeptide? | PolyPeptide's last 12 months revenue is $470M. |
| What is the current revenue growth of PolyPeptide? | PolyPeptide revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of PolyPeptide? | Current revenue multiple of PolyPeptide is 2.3x. |
| Is PolyPeptide profitable? | Yes, PolyPeptide is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of PolyPeptide? | PolyPeptide's last 12 months EBITDA is $55M. |
| What is PolyPeptide's EBITDA margin? | PolyPeptide's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of PolyPeptide? | Current EBITDA multiple of PolyPeptide is 19.8x. |
| What is the current FCF of PolyPeptide? | PolyPeptide's last 12 months FCF is ($46M). |
| What is PolyPeptide's FCF margin? | PolyPeptide's last 12 months FCF margin is (10%). |
| What is the current EV/FCF multiple of PolyPeptide? | Current FCF multiple of PolyPeptide is (23.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.